| Primary |
| Hypertension |
32.5% |
| Product Used For Unknown Indication |
25.3% |
| Drug Use For Unknown Indication |
8.0% |
| Cardiac Failure Congestive |
4.2% |
| Diabetes Mellitus |
4.2% |
| Acute Myocardial Infarction |
3.4% |
| Blood Pressure |
3.0% |
| Prophylaxis |
2.5% |
| Blood Pressure Increased |
1.7% |
| Cardiac Disorder |
1.7% |
| Coronary Artery Disease |
1.7% |
| Peripheral Vascular Disorder |
1.7% |
| Asthma |
1.3% |
| Behcet's Syndrome |
1.3% |
| Blood Pressure Systolic Increased |
1.3% |
| Dental Operation |
1.3% |
| Hypothyroidism |
1.3% |
| Infection |
1.3% |
| Nephrogenic Anaemia |
1.3% |
| Pyrexia |
1.3% |
|
| Angioedema |
14.5% |
| Pneumonia |
9.2% |
| Linear Iga Disease |
6.6% |
| Medication Error |
6.6% |
| Polyglandular Autoimmune Syndrome Type Iii |
6.6% |
| Cough |
5.3% |
| Hypertension |
5.3% |
| Renal Failure Acute |
5.3% |
| Vomiting |
5.3% |
| Drug Hypersensitivity |
3.9% |
| Hypoglycaemia |
3.9% |
| Product Quality Issue |
3.9% |
| Swollen Tongue |
3.9% |
| White Blood Cell Count Increased |
3.9% |
| Asthma |
2.6% |
| Blood Creatinine Increased |
2.6% |
| Blood Pressure Inadequately Controlled |
2.6% |
| Death |
2.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.6% |
| Hyperkalaemia |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
28.6% |
| Hypertension |
28.0% |
| Drug Use For Unknown Indication |
12.6% |
| Diabetes Mellitus |
4.0% |
| Coronary Artery Disease |
3.9% |
| Acute Myocardial Infarction |
3.7% |
| Cardiac Failure |
3.2% |
| Atrial Fibrillation |
2.3% |
| Malignant Hypertension |
1.8% |
| Essential Hypertension |
1.6% |
| Arthralgia |
1.4% |
| Pain |
1.2% |
| Arrhythmia |
1.2% |
| Cardiac Disorder |
1.1% |
| Prophylaxis |
1.1% |
| Glaucoma |
1.0% |
| Parkinson's Disease |
1.0% |
| Gout |
0.8% |
| Type 2 Diabetes Mellitus |
0.8% |
| Anxiety |
0.7% |
|
| Renal Failure Acute |
13.1% |
| Hypoglycaemia |
10.0% |
| Ventricular Tachycardia |
9.4% |
| Vomiting |
8.8% |
| Hypertension |
5.6% |
| Thrombotic Thrombocytopenic Purpura |
5.6% |
| Drug Ineffective |
4.4% |
| Psychomotor Retardation |
4.4% |
| Angioedema |
3.8% |
| Blindness |
3.8% |
| Drug Interaction |
3.8% |
| Somnolence |
3.8% |
| Tachycardia |
3.8% |
| Blood Pressure Increased |
3.1% |
| Dyspnoea |
3.1% |
| Renal Failure |
3.1% |
| Urticaria |
3.1% |
| Circulatory Collapse |
2.5% |
| Death |
2.5% |
| Hypotension |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.8% |
| Hypertension |
20.1% |
| Drug Use For Unknown Indication |
16.7% |
| Rheumatoid Arthritis |
5.9% |
| Diabetes Mellitus |
4.9% |
| Pain |
2.8% |
| Prophylaxis |
2.8% |
| Blood Pressure |
2.7% |
| Depression |
2.5% |
| Cardiac Disorder |
2.3% |
| Type 2 Diabetes Mellitus |
2.0% |
| Osteoporosis |
1.2% |
| Blood Cholesterol Increased |
1.2% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
| Asthma |
1.1% |
| Hiv Infection |
1.1% |
| Anxiety |
1.0% |
| Atrial Fibrillation |
1.0% |
| Cardiac Failure |
1.0% |
| Anticoagulant Therapy |
0.8% |
|
| Vomiting |
11.1% |
| Weight Increased |
8.5% |
| Weight Decreased |
7.6% |
| Pneumonia |
7.0% |
| Myocardial Infarction |
6.2% |
| Urinary Tract Infection |
5.9% |
| Pain |
5.4% |
| Somnolence |
5.0% |
| Thrombocytopenia |
5.0% |
| Death |
4.6% |
| Renal Failure |
4.4% |
| Drug Ineffective |
3.8% |
| Sepsis |
3.7% |
| Pyrexia |
3.5% |
| Tremor |
3.3% |
| Syncope |
3.2% |
| Vision Blurred |
3.1% |
| Cardiac Failure |
2.9% |
| Dyspnoea |
2.9% |
| Ventricular Fibrillation |
2.9% |
|
| Interacting |
| Dementia |
25.3% |
| Hypertension |
18.4% |
| Product Used For Unknown Indication |
17.2% |
| Acute Myocardial Infarction |
9.2% |
| Drug Use For Unknown Indication |
4.6% |
| Arrhythmia |
2.3% |
| Chronic Myeloid Leukaemia |
2.3% |
| Diabetes Mellitus |
2.3% |
| Gastrooesophageal Reflux Disease |
2.3% |
| Hepatitis C |
2.3% |
| Hypercholesterolaemia |
2.3% |
| Hyperuricaemia |
2.3% |
| Abdominal Pain Upper |
1.1% |
| Atrial Fibrillation |
1.1% |
| Cough |
1.1% |
| Gout |
1.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
| Renal Failure |
1.1% |
| Rheumatoid Arthritis |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
|
| Atrial Flutter |
14.3% |
| Hypertension |
14.3% |
| Death |
7.1% |
| Drug Interaction |
7.1% |
| Hyperkalaemia |
7.1% |
| Hypotension |
7.1% |
| Neutropenia |
7.1% |
| Oedema |
7.1% |
| Product Substitution Issue |
7.1% |
| Renal Failure |
7.1% |
| Thrombocytopenia |
7.1% |
| Transaminases Increased |
7.1% |
|
